NHL CAR-T therapy market reaches $3.2b

Market reached $3.2b in 2025, with the US accounting for 59% of total value.

The CAR-T cell therapy market for non-Hodgkin lymphoma (NHL) reached $3.2b across the seven major markets (7MM) in 2025, according to DelveInsight.

The 7MM consists of the US, EU4–which as Germany, France, Italy, and Spain–the UK, and Japan. The US alone accounted for 59% of total market size.

The market is projected to grow at a compound annual growth rate of about 7% from 2026 to 2036, supported by wider clinical adoption, expanding treatment indications, and new therapies entering the market.

“The entry of emerging and late-stage CAR T-cell therapies is expected to intensify competition in the CAR T-cell therapy landscape for NHL during the forecast period,” said Aparna Thakur, Project Manager of Forecasting at DelveInsight.

Growth is being driven by demand for treatments for relapsed or refractory NHL, particularly aggressive subtypes such as diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. 

CAR-T therapies are also seeing broader use in earlier treatment settings and across additional lymphoma subtypes.

Approved therapies such as TECARTUS, BREYANZI, KYMRIAH, and YESCARTA are competing alongside pipeline candidates under development.

Drugmakers are developing next-generation CAR-T platforms, including allogeneic therapies aimed at broadening patient access and in vivo CAR-T approaches that generate CAR-T cells inside the patient’s body after infusion.

Across the 7MM, selected CAR-T indications in NHL recorded about 159,000 incident cases in 2025. DLBCL accounted for the largest number of incident cases at about 78,000.